Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + vistusertib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel + vistusertib is a combination therapy consisting of the chemotherapeutic agent paclitaxel and the targeted small molecule inhibitor vistusertib. Paclitaxel is a microtubule-stabilizing agent that disrupts cell division by inhibiting microtubule depolymerization, leading to mitotic arrest and apoptosis in cancer cells. Vistusertib (AZD2014) is an oral dual inhibitor of mTOR complexes 1 and 2 (mTORC1/2), which are key regulators of cell growth, proliferation, survival, and resistance mechanisms in cancer. The combination has been investigated primarily for platinum-resistant high-grade serous ovarian carcinoma (PR-HGSC) and squamous non-small cell lung cancer (SqNSCLC). Early-phase clinical trials demonstrated manageable toxicity profiles with evidence of tumor shrinkage in both ovarian and lung cancers; however, larger randomized studies did not show significant improvement in progression-free or overall survival compared to standard chemotherapy alone[1][3][4][6].
- Brand names
- Taxol
- Other names
- paclitaxel and vistusertibweekly paclitaxel plus vistusertib
02
Targets
TUBB (Tubulin (alpha and beta subunits))Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on paclitaxel + vistusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + vistusertib.